Cyclodextrin-impregnated masks to prevent the transmission of coronavirus
CycloLab’s submission to InnoCentive Challenge 9934291 – New Technologies to Prevent the Transmission of Coronavirus led to a favorable evaluation.
Category: Pharma applications
Marinus Awarded BARDA Contract to Develop SBECD-enabled Ganaxolone for Treatment of Refractory Status Epilepticus
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it has
Cyclodextrin counteracts obesity associated with various diseases including susceptibility for Covid-19
Obesity has become a worldwide health crisis and is associated with a plethora of comorbidities. Cardiovascular disease (CVD) and type
Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds: a patent evaluation of US2019343869(A1)
Introduction: Antimicrobial resistance is one of the major scourges for healthcare worldwide, therefore novel investigational approaches are needed to potentiate and
Nitric oxide in the treatment of coronavirus disease (COVID-19)
„Inhaled nitric oxide dilates or widens arteries to allow more blood to flow through the lungs. It also relaxes the
BIO Investor Forum – Digital Oct. 13-15, 2020
BIO Investor Forum Digital: The industry’s leading biopharma executives and BD professionals from public and venture-stage growth companies, and top
Gelatin/β–Cyclodextrin Bio–Nanofibers as Respiratory Filter Media for Filtration of Aerosols
This study reports gelatin/β–cyclodextrin composite nanofiber mats with dual function air filtration ability (particulate matter as well as volatile organics
Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Potential COVID-19 therapeutics from a rare disease: utilization of lipid dysregulation to combat viral infectivity
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
FDA Expands EUA for SBECD-enabled Remdesivir
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With